Homepage
Author:
InnoCare Pharma
Posted Date:
June 5, 2026
Phase IIb Study Results of InnoCare’s Orelabrutinib in Patients with SLE Presented at 2026 EULAR
InnoCare Pharma
June 5, 2026
ASCO 2026 | Updated Data from an Oral Presentation of InnoCare’s Novel BCL2 Inhibitor Mesutoclax in MDS and AML Released
InnoCare Pharma
June 2, 2026
InnoCare Announces the Acceptance of New Drug Application for Orelabrutinib in Primary Immune Thrombocytopenia in China
InnoCare Pharma
May 28, 2026
InnoCare Announces Approval of Orelabrutinib in Australia
InnoCare Pharma
May 27, 2026
2026 ASCO | Pivotal Data of InnoCare’s Novel BCL2 Inhibitor Mesutoclax Released
InnoCare Pharma
May 23, 2026
InnoCare Announce First Subject Dosed in Phase 1 Clinical Trial of ICP-054, a Novel Potentially Best-in-Class Oral IL-17AA/AF Inhibitor
InnoCare Pharma
May 21, 2026
InnoCare Announces Approval of a Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for Sjögren’s Syndrome in China
InnoCare Pharma
May 7, 2026
InnoCare Announces Approval of Clinical Trial of Novel CDH7 targeted ADC ICP-B208 in China
InnoCare Pharma
May 6, 2026
InnoCare Announces First Patient Dosed in Phase III Trial of Orelabrutinib for SLE
InnoCare Pharma
April 28, 2026
InnoCare Releases 2026 Q1 Results: Strong Revenue Growth and Sustained Profitability
InnoCare Pharma
April 23, 2026
1
2
Next
